INE-1001 is being developed for Dry Eye Disease (DED) and is progressing towards a first-in-human Phase 1/2a PoC study to be initiated in 2026
Preclinical evidence
In healthy mice, INE-1001 exhibited a moderate effect on corneal sensitivity not desensitizing the ocular surface
In a DED model in mice, INE-1001 showed efficacy reducing a DED Symptom (exacerbated corneal sensivity) and DED signs such as tear quality and corneal staining
INE-1001 presented good ocular tolerability and low sytemic exposure in 14-day repeated-dosing study in rabbits